09/12/2025 13:04
EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada 
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Alliance/Agreement br/ Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® Pembrolizumab, in the...
04/12/2025 06:30
EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Agreement br/ Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region...
24/11/2025 06:30
EQS-News: NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Miscellaneous br/ NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy ...
20/11/2025 17:00
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
html xmlns=http://www.w3.org/1999/xhtmlbodytable border=trtd p OriginalResearch: Formycon AG from First Berlin Equity Research GmbH br/br/ 20.11.2025 / 17:00 CET/CESTbr/ Dissemination of a Research, transmitted by a...
20/11/2025 06:30
EQS-News: Ranibizumab Biosimilar Epruvy® launched in Germany
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Product Launch br/ Ranibizumab Biosimilar Epruvy® launched in Germany br/br/ 20.11.2025 / 06:30 CET/CESTbr/ The issuer is solely...
17/11/2025 06:30
EQS-News: Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® (dupilumab) adds another growth driver to the biosimilar portfolio
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Miscellaneous br/ Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent® dupilumab adds another growth driver to the...
13/11/2025 06:30
EQS-News: Formycon publishes nine-month results and confirms guidance – Pipeline progress and strong partnerships drive fiscal year 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: 9 Month figures/Quarterly / Interim Statement br/ Formycon publishes ninemonth results and confirms guidance – Pipeline progress and strong partnerships...
30/10/2025 06:30
EQS-News: Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Miscellaneous br/ Formycon invites to Conference Call on 2025 NineMonth Results and announces Participation in Investor Conferences in the 4th Quarter of 2025...
21/10/2025 06:30
EQS-News: Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Market Launch/Product Launch br/ Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in...